FirstAlerts

Adaptive Biotechnologies CEO Chad M. Robins Sells $14.8 Million in Common Stock

Chad M. Robins sold 597,271 shares of Adaptive Biotechnologies Corp on August 17, 2026, according to an official SEC filing.

2 reports on this incident · first at Aug 19, 2026, 10:22 p.m. ET

By AI ReporterWritten Aug 19, 2026, 10:52 p.m. ET
According to an official SEC filing, , of , sold 597,271 shares of common stock on August 17, 2026. The sale was executed at a price of $ per share, totaling $14,812,474. Official records state that the transaction was not conducted under a trading plan. Following the sale, Robins holds 2,183,043 shares in the , Washington-based company.

Earlier reports

  1. Aug 19, 2026, 10:22 p.m. ETFirst report

    Adaptive Biotechnologies CEO Chad M. Robins Sells $14.8 Million in Stock

    According to an SEC Form 4 insider transaction filing, Chad M. Robins, CEO and Chairman of Adaptive Biotechnologies Corp (ticker ADPT), sold 597,271 shares of common stock on August 17, 2026. The transaction totaled $14,812,474 at a price of $25.08 per share.

    Following the sale, Robins holds 2,183,043 shares. The official record from the Seattle, WA-based company notes that the sale was not made under a trading plan.

Was this report accurate and useful?

Sources

Revision history

  1. Version 120 Aug 2026, 02:52current

    First published.

  2. Version 120 Aug 2026, 02:22current

    First published.

How we work

This site models an investigative reporter rather than a wire desk. The aim is the most complete, accurate and timely account we can assemble — all three, not a trade between them. Reports go out within minutes of the coverage they are built from, carrying context a newsroom would otherwise need a day and a records request to gather: what has happened at this place before, what the operator’s record is, which aircraft it actually was.

Reports are built from primary sources — accident and court records, official registries, weather observations, agency statements — and from reputable news organisations, each named where their reporting is used. Facts are extracted before anything is written, and every one must be supported by a quotation found in the source itself; the model that writes the report is given only those verified facts and never sees the article, so it cannot introduce a detail no source stated.

Where sources disagree we publish the disagreement, attributed, rather than picking a figure. Where a fact comes from a record rather than a reporter, we say so, and the language matches: an instrument reading is never described as something anyone confirmed. Some things are deliberately withheld — a suspect is not named until an agency names them on the record, victims until families or officials release them — and corrections appear as visible revisions, never as silent edits.

None of that makes a report true. A quotation check proves a source said something, not that it was right, and an automated system can be confidently wrong in ways the checks do not catch. If something here is wrong, the feedback above is how it gets found. The full methodology, including what we refuse to publish.

Adaptive Biotechnologies CEO Chad M. Robins Sells $14.8 Million in Common Stock — FirstAlerts